The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABIO Detailed Price Forecast - CNN Money||View ABIO Detailed Summary - Google Finance|
|View ABIO Detailed Summary - Yahoo! Finance||View ABIO Stock Research & Analysis - Zacks.com|
|View ABIO Trends & Analysis - Trade-Ideas||View ABIO Major Holders - Barrons|
|View ABIO Call Transcripts - NASDAQ||View ABIO Breaking News & Analysis - Seeking Alpha|
|View ABIO Annual Report - CompanySpotlight.com||View ABIO OTC Short Report - OTCShortReport.com|
|View ABIO Fundamentals - TradeKing||View ABIO SEC Filings - Bar Chart|
|View Historical Prices for ABIO - The WSJ||View Performance/Total Return for ABIO - Morningstar|
|View the Analyst Estimates for ABIO - MarketWatch||View the Earnings History for ABIO - CNBC|
|View the ABIO Earnings - StockMarketWatch||View ABIO Buy or Sell Recommendations - MacroAxis|
|View the ABIO Bullish Patterns - American Bulls||View ABIO Short Pain Metrics - ShortPainBot.com|
|View ABIO Stock Mentions - StockTwits||View ABIO Stock Mentions - PennyStockTweets|
|View ABIO Stock Mentions - Twitter||View ABIO Investment Forum News - Investor Hub|
|View ABIO Stock Mentions - Yahoo! Message Board||View ABIO Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABIO - SECform4.com||View Insider Transactions for ABIO - Insider Cow|
|View ABIO Major Holdings Summary - CNBC||View Insider Disclosure for ABIO - OTC Markets|
|View Insider Transactions for ABIO - Yahoo! Finance||View Institutional Holdings for ABIO - NASDAQ|
|View ABIO Stock Insight & Charts - FinViz.com||View ABIO Investment Charts - StockCharts.com|
|View ABIO Stock Overview & Charts - BarChart||View ABIO User Generated Charts - Trading View|
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
Posted on Monday March 18, 2019
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Left Ventricles” was recently published in the Journal of the American College of Cardiology (JACC) (http://www.onlinejacc.org/content/73/10/1173). The lead author on the paper is University of Colorado molecular biologist Carmen Sucharov, PhD and the senior author is Michael R. Bristow MD, PhD, ARCA’s Chief Executive Officer, who is also the Director of the University of Colorado Cardiovascular Institute (CU CVI) Section of Pharmacogenomics.
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
Posted on Wednesday March 06, 2019
WESTMINSTER, Colo., March 06, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
Posted on Wednesday February 27, 2019
WESTMINSTER, Colo., Feb. 27, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
Posted on Wednesday February 20, 2019
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure.